BPC issues opinions on 11 active substance approvals

The Biocidal Products Committee has issued opinions on active substance approvals for the following substances:

  • Reaction products of paraformaldehyde and 2-hydroxypropylamine (ratio 3:2)
  • Product type 2 (disinfectants and algaecides not intended for direct application to humans or animals)
  • Product type 6 (preservatives for products during storage)
  • Product type 11 (preservatives for liquid-cooling and processing systems)
  • Product type 12 (slimicides)
  • Product type 13 (working or cutting fluid preservatives)
  • Reaction products of paraformaldehyde and 2-hydroxypropylamine (ratio 1:1)
  • Product type 2 (disinfectants and algaecides not intended for direct application to humans or animals)
  • Product type 6 (preservatives for products during storage)
  • Product type 11 (preservatives for liquid-cooling and processing systems)
  • Product type 13 (working or cutting fluid preservatives)
  • Imiprothrin [CAS# 72963-72-5]
  • Product type 18 (insecticides, acaricides and products to control other arthropods)
  • MBIT [CAS# 2527-66-4]
  • Product type 6 (preservatives for products during storage)

Upon completion of an active substance evaluation by an evaluating Competent Authority (eCA), the eCA submits a report for peer review at the ECHA’s Biocidal Products Committee (BPC). Following these discussions, the BPC may issue a decision on approval or non-approval of the active substance in the appropriate product-type. The BPC opinion document contains details on the evaluation process and the proposed conditions of a subsequent approval; the document also contains elements to be taken into account when authorising biocidal products containing the active substance. It should be noted that the approval/non-approval of an active substance only becomes official when the EU Commission decides to approve/not approve the active substance having taking into consideration the BPC opinion, and subsequent applications for product authorisation can only be submitted once an active substance is officially approved. The BPC opinion can however act as a useful trigger to companies to begin preparing for submission of a product authorisation application.

Chemtrac, 28 July 2017 ; https://www.chemtracglobal.com/news